Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
DesmopressinCat. No. 3396 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
Biological Activity
Synthetic vasopressin analog that acts as an agonist at V1B and V2 receptors (EC50 values are 11.4 and 23.9 nM and Ki values are 5.84 and 65.9 nM respectively). Prevents polycystic kidney disease formation and exhibits antidiuretic, antiproliferative, hemostatic and hypotensive activity in vivo.Technical Data
M.Wt:(Modifications: X = Mpr, Arg-8 = D-Arg, Gly-9 = C-terminal amide, Cyclized = X-1 - Cys-6)
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
References
Saito et al (1997) 1-Desamino-8-D-arginine vasopressin (DDAVP) as an agonist on V1b vasopressin receptor. Biochem.Pharmacol. 53 1711. PMID: 9264324.
Gomez et al (2006) Desmopressin and other synthetic vasopressin analogues in cancer treatment. Bull.Cancer 93 E7. PMID: 16517412.
Torres (2008) Vasopressin antagonists in polycystic kidney disease. Semin.Nephrol. 28 306. PMID: 18519091.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: Desmopressin, supplier, Synthetic, vasopressin, analog, V1B, V2, agonists, Receptors, Vasopressin
Quick Order
Find multiple products by catalog number
7-TM Receptor Signaling
Written by T. Kenakin et al
'Seven Transmembrane Receptor Signaling' highlights the multiple behaviors of 7-TMs including G-protein-dependent and -independent signaling as well as the concept of collateral efficacy
Antidepressants - Current and Future Targets
Written by P. Skolnich et al
'Antidepressants - Current and Future Targets' provides an overview of the current and future targets for the treatment of major depressive disorder.
New Products in this Area
Oxytocin analog
ML 221Apelin receptor (APJ) antagonist
Q94 hydrochlorideNegative allosteric modulator at PAR1 receptor
FSLLRY-NH2PAR2 peptide antagonist
SB 611812Urotensin-II (UT) antagonist; attenuates cardiac dysfunction
TC-MCH 7cSelective melanin-concentrating hormone receptor 1 (MCH1R) antagonist
CYM 9484Potent NPY Y2 receptor antagonist
Tocris Events
Win a Kindle
11th Annual Meeting of the International Society for Stem Cell Research
June 12 - 15, 2013
Boston, MA
Booth Number: 213